Bharat Biotech to sell Covaxin in US, signs deal with Ocugen
Bharat Biotech will supply initial doses to be used in the US upon Ocugen s receipt of an EUA from the US regulatory authorities
PB Jayakumar | February 3, 2021 | Updated 13:51 IST
Covaxin was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV)
Hyderabad-based Bharat Biotech has entered into an exclusive deal with US biopharmaceutical company Ocugen to commercialise Covaxin, the first indigenous coronavirus vaccine developed in India, in the US market.
Under the terms of the agreement, Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including EUA) and commercialisation for the US market. Bharat Biotech will supply initial doses to be used in the US upon Ocugen s receipt of an EUA from the US regulatory authorities.
Ocugen, Bharat Biotech to commercialise Covaxin in US
February 02, 2021
To share US commercialisation profits
Ocugen, Inc., a biopharmaceutical company, and Hyderabad-based Bharat Biotech have announced an agreement to co-develop, supply and commercialise the latter’s Covaxin, an advanced stage whole-virion inactivated Covid-19 vaccine candidate, for the US market.
Under the terms of the agreement, Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including EUA) and commercialisation for the US market.
Bharat Biotech will supply initial doses to be used in the US upon Ocugen’s receipt of an EUA. In addition, it will support the technology transfer for manufacturing in the US. In consideration for the exclusive licence to the US market, Ocugen will share the profits from the sale of Covaxin in the US market with Bharat Biotech, with Ocugen retaining 45 per cent of the profits.
Next-gen Covid-19 vaccines may be needed to tackle emerging variants, say scientists
Next-gen Covid-19 vaccines may be needed to tackle emerging variants, say scientists
PTI | Jan 28, 2021, 12:41 IST
NEW DELHI: The spread of Covid-19 variants is not an immediate problem but it s time already for next-gen preventives to tackle them, say scientists as countries fine-tune their vaccine dissemination programmes and the race to put more vaccines in the market gathers pace.
Work on vaccines will have to continue on parallel tracks “one to tackle the SARS-CoV-2 virus with first generation vaccines and the other to prepare for possible mutations and new variants say experts as they map the future course of the infection.
New Delhi, January 27
The spread of COVID-19 variants is not an immediate problem but it’s time already for next-gen preventives to tackle them, say scientists as countries fine-tune their vacc